The prognostic value of plasma fibrinogen concentrations of patients with ST-elevation myocardial infarction and treated by primary percutaneous coronary intervention: A cautionary message

References

• Ottani F, Galvani M. Prognostic role of haemostatic markers in acute coronary syndromes patients. Clin Chim Acta 2001;311:33–9.
   PubMedGoogle Scholar
• Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799–809.
   PubMed Web of Science ®Google Scholar
• Welsh P, Woodward M, Rumley A, Lowe G. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Brit J Haematol 2008;141:852–61.
   PubMed Web of Science ®Google Scholar
• Linko E, Waris E. Plasma protein changes after acute myocardial infarction: alpha 2-globulin and fibrinogen. Scand J Clin Lab Invest 1955;7:135–40.
   PubMed Web of Science ®Google Scholar
• Munkvad S, Nieuwenhuizen W, Jespersen J. Plasma HMW fibrinogen in patients with ischaemic heart disease. Scand J Clin Lab Invest 1990;50:347–9.
   PubMedGoogle Scholar
• Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501–5.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183–6.
   PubMed Web of Science ®Google Scholar
• Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation 1997;96:4204–10.
   PubMed Web of Science ®Google Scholar
• Biasucci LM; CDC; AHA.CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:e560–7.
   PubMed Web of Science ®Google Scholar
• Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovié M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980;1:1050–4.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Arveiler D, Amouyel P, Dos Santos C, Evans A, Luc G, Ferrières J, Juhan-Vague I; Prospective Epidemiological Study of Myocardial Infarction. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. Atherosclerosis 2003;166:103–9.
   PubMedGoogle Scholar
• Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54–9.
   PubMed Web of Science ®Google Scholar
• Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999;19:1776–83.
   PubMed Web of Science ®Google Scholar
• Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. J Am Coll Cardiol 1999; 33:1347–52.
   PubMed Web of Science ®Google Scholar
• Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477–82.
   PubMed Web of Science ®Google Scholar
• Swahn E, von Schenck H, Wallentin L. Plasma fibrinogen in unstable coronary artery disease. Scand J Clin Lab Invest 1989;49:49–54.
   PubMed Web of Science ®Google Scholar
• Mahmud E, Cavendish JJ, Tsimikas S, Ang L, Nguyen C, Bromberg-Marin G, Schnyder G, Keramati S, Palakodeti V, Penny WF, DeMaria AN. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol 2007;49:2163–71.
   PubMedGoogle Scholar
• Rahel BM, Visseren FL, Suttorp MJ, Plokker TH, Kelder JC, de Jongh BM, Bouter KP, Diepersloot RJ. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res 2003;60:136–40.
   PubMed Web of Science ®Google Scholar
• Ziakas A, Gavrilidis S, Giannoglou G, Souliou E, Gemitzis K, Kalampalika D, Vayona MA, Pidonia I, Parharidis G, Louridas G. In-hospital and long-term prognostic value of fibrinogen, CRP, and IL-6 levels in patients with acute myocardial infarction treated with thrombolysis. Angiology 2006;57:283–93.
   PubMed Web of Science ®Google Scholar
• Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, Braunwald B. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol 1996;78:142–7.
   PubMed Web of Science ®Google Scholar
• Toss H, Lindahl B, Siegbahn A,Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997; 96:4204–10.
   PubMedGoogle Scholar
• Solheim S, Grøgaard HK, Hoffmann P, Arnesen H, Seljeflot I. Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest 2008;68:555–62.
   PubMed Web of Science ®Google Scholar
• Bennermo M, Held C, Hamsten A, Strandberg LE, Ericsson CG, Hansson LO, Tornvall P. Prognostic value of plasma C-reactive protein and fibrinogen determinations in patients with acute myocardial infarction treated with thrombolysis. J Intern Med 2003;254:244–50.
   PubMedGoogle Scholar
• Pollak H, Fischer M, Fritsch S, Enenkel W. Are admission plasma fibrinogen levels useful in the characterization of risk groups after myocardial infarction treated with fibrinolysis? Thromb Haemost 1991;66:406–9.
   PubMedGoogle Scholar
• The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29:2909–45.
   PubMedGoogle Scholar
• Hassan AK, Bergheanu SC, Hasan-Ali H, Liem SS, van der Laarse A, Wolterbeek R, Atsma DE, Schalij MJ, Jukema JW. Usefulness of peak troponin-T to predict infarct size and long-term outcome in patients with first acute myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 2009;103:779–84.
   PubMedGoogle Scholar
• Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009;30:2838–44.
   PubMed Web of Science ®Google Scholar
• Accessed 17 May 2011 from: http://www.renal.org/aboutus/the association.aspx
   Google Scholar
• Lenzen MJ, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, Sechtem U, Stahle E, Widimsky P, de Jaegere P, Scholte op Reimer WJ, Mercado N, Wijns W; European Society of Cardiology. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J. 2005;26: 1169–79.
   PubMed Web of Science ®Google Scholar
• Wagner C, Dati F. Fibrinogen. In: Lothar T, editor. Clinical laboratory diagnostics. Frankfurt/Main, Germany: TH-Books Verlagsgesellschaft mbH; 1998.
   Google Scholar
• Ricós C, Cava F, García-Lario JV, Hernández A, Iglesias N, Jiménez CV, Minchinela J, Perich C, Simón M, Domenech MV, Alvarez V. The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Scand J Clin Lab Invest 2004;64:175–84.
   PubMed Web of Science ®Google Scholar
• Accessed 17 May 2011 from: http://www.westgard.com/biodatabase1.htm.
   Google Scholar
• The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598–660.
   PubMedGoogle Scholar
• Baer HJ, Glynn RJ, Hu FB, Hankinson SE, Willett WC, Colditz GA, Stampfer M, Rosner B. Risk factors for mortality in the nurses’ health study: a competing risks analysis. Am J Epidemiol 2011;173:319–29.
   PubMed Web of Science ®Google Scholar
• Song JX, Ahn CW. An evaluation of methods for the stratified analysis of clustered binary data in community intervention trials. Stat Med 2003;22:2205–16.
   PubMedGoogle Scholar
• Deslandes E, Chevret S. Joint modelling of multivariate longitudinal data and the dropout process in a competing risk setting: application to ICU data. BMC Med Res Methodol 2010;10:69.
   PubMedGoogle Scholar
• Peduzzi P, Concato J, Feinstein AR, Holford TR . Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48: 1503–10.
   PubMed Web of Science ®Google Scholar
• Accessed 17 May 2011 from: http://www.cran.r-project.org/package = survival
   Google Scholar
• Ketch TR, Turner SJ, Sacrinty MT, Lingle KC, Applegate RJ, Kutcher MA, Sane DC. Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting. Am Heart J 2008;156:234–40.
   PubMedGoogle Scholar
• Panteghini M, Cuccia C, Bonetti G, Giubbini R, Pagani F, Bonini E. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 2002;48: 1432–6.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Mort EA, Nordberg P, Chang Y, Cadigan ME, Mylott L, Ananian LV, Thompson BT, Fessler M, Warren W, Wheeler A, Jordan M, Fifer MA. A utilization management intervention to reduce unnecessary testing in the coronary care unit. Arch Intern Med 2002;162:1885–90.
   PubMedGoogle Scholar
• Turner SJ, Ketch TR, Gandhi SK, Sane DC. Routine haematological clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J 2008;155: 806–16.
   PubMed Web of Science ®Google Scholar
• Zacharowski K, Zacharowski P, Reingruber S, Petzelbauer P. Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction. J Mol Med 2006; 84:469–77.
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schömig A, Kastrati A, Sibbing D. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010;104: 1193–200.
   PubMed Web of Science ®Google Scholar
• Undas A, Brummel-Ziedins KE, Potaczek DP, Stobierska-Dzierzek B, Bryniarski L, Szczeklik A, Mann KG. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost 2006;4:2397–404.
   PubMed Web of Science ®Google Scholar
• Iijima R, Byrne RA, Ndrepepa G, Braun S, Mehilli J, Berger PB, Schömig A, Kastrati A. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart 2009;95:107–12.
   PubMed Web of Science ®Google Scholar
• Harrell FE, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 1985;69: 1071–7.
   PubMedGoogle Scholar
• Kuch B, von Scheidt W, Kling B, Heier M, Hoermann A, Meisinger C. Differential impact of admission C-reactive protein levels on 28-day mortality risk in patients with ST-elevation versus non-ST-elevation myocardial infarction (from the Monitoring Trends and Determinants on Cardiovascular Diseases[MONICA]/Cooperative Health Research in the Region of Augsburg [KORA] Augsburg Myocardial Infarction Registry). Am J Cardiol 2008;102: 1125–30.
   PubMed Web of Science ®Google Scholar